Clinical Trial Detail

NCT ID NCT02601950
Title A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Epizyme, Inc.
Indications

rhabdoid cancer

synovial sarcoma

Advanced Solid Tumor

Therapies

Tazemetostat

Age Groups: adult senior

Additional content available in CKB BOOST